207
views
2
recommends
+1 Recommend
1 collections
    1
    shares
      scite_
       
      • Record: found
      • Abstract: found
      • Conference Proceedings: found
      Is Open Access

      Organ-agnostic precision oncology

      Published
      proceedings-article
        1 ,
      ScienceOpen
      RExPO22
      2-3 September, 2022
      Oncology, Diagnostics, Precision, NGS, qPCR, liquid biopsy, RNA-Seq, WES, epigenetics, off-label use
      Bookmark

            Abstract

            When we think of cancer, we mainly use the organs from which it originated as designation and therapy is for the most part specific to this tissue type. That said, each cancer can be unique, and the molecular pattern of the malignant cells can vastly differ between individuals. Currently though all patients with a similar cancer type undergo similar therapies. By utilising genomic, transcriptomic and in some cases epigenetic data, it is possible to tailor therapy options for the individual with these diagnostic tools. The basis of the analysis can be the tissue or even a liquid biopsy and ranges from qPCR of specific markers to next generation sequencing (NGS) of the whole exome (WES) or the complete transcriptome (RNA-Seq). For the interpretation, publicly available databases that link mutations and expression of target genes to active compounds are used. In addition, pathway and multivariant analysis to find likely connections that are to some degree associated with pharmacogenetic mode of action are interpolated. The combined findings can help to generate a personalised list of compounds that are potentially effective for the cancer at hand. Drug and therapeutic recommendations can be already approved for the specific disease based on tissue type, other malignancies, or have completely different indications altogether in an off-label use. To ensure safety, pharmacological interactions have to be checked in-silico for unproblematic combinational therapy. If the organ of origin gives the basic information, precision oncology employing sufficient data can widen the range of options in this dire disease.

            Content

            Author and article information

            Conference
            ScienceOpen
            29 August 2022
            Affiliations
            [1 ] GeneSurge GmbH
            Author notes
            Author information
            https://orcid.org/0000-0001-7473-8321
            Article
            10.14293/S2199-1006.1.SOR-.PPPEDSDP.v1
            06a903dc-ca37-461d-a6f6-202d488e06d6

            This work has been published open access under Creative Commons Attribution License CC BY 4.0 , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Conditions, terms of use and publishing policy can be found at www.scienceopen.com .

            RExPO22
            Maastricht, Netherlands
            2-3 September, 2022
            History
            : 25 August 2022

            Data sharing not applicable to this article as no datasets were generated or analysed during the current study.
            epigenetics,WES,RNA-Seq,liquid biopsy,qPCR,NGS,Precision,Diagnostics,Oncology,off-label use

            Comments

            Comment on this article